New York Times has reported that Indian Pharmaceutical Industry once known for making cheap generics knocks off western medicines. It is on track to grow 13% approximately $24 billion giving broader shift in Indian Economy.
Times, has also reported that the growth might be due to strengthening the patent laws in India and also on the cost structure followed in US for name-brand generics.
Indian companies are having lot to offer including the generics version of cancer and epilepsy medications that are bound for United States and cost advantage is also huge. It is expanding as a major drug producer.
No comments yet.
You must be logged in to post a comment.